Australia Launches 2026 Flu Vaccination Program Amid Rising Cases

Australia has officially commenced its 2026 influenza vaccination program, with public health authorities nationwide strongly urging residents to get vaccinated. This critical initiative unfolds as influenza cases are on the rise across the country and in specific regions, coinciding with the continued circulation of other significant respiratory infections like RSV and COVID-19.

Health professionals, including General Practitioners and pharmacists, are central to both vaccine administration and patient education efforts this season. The Australian Technical Advisory Group on Immunisation (ATAGI) has also released its updated guidelines for the year, providing crucial recommendations.

Australia's 2026 influenza vaccination program is underway, with health authorities urging residents to get vaccinated as flu cases begin to rise nationally, alongside other respiratory infections.

The Current Respiratory Threat

In 2026, a total of nearly 22,088 laboratory-confirmed influenza cases have already been reported nationwide. This early surge follows a formidable 2025 season, which saw over 502,000 cases – the highest number recorded in more than 25 years.

Regionally, areas such as the Cape York, Torres Strait, and Northern Peninsula Area are experiencing a notable increase in respiratory infections, encompassing influenza, respiratory syncytial virus (RSV), and COVID-19. For instance, the community of Weipa has reported 90 influenza cases year-to-date in 2026, a significant increase compared to just 15 during the same period last year.

Public health officials anticipate a potentially significant flu season for 2026.

2026 Vaccination Program: What You Need to Know

The new seasonal influenza vaccination is being progressively rolled out across Australia. In Queensland, vaccines are scheduled to become available from March 1, with wider availability generally recommended when vaccines become accessible in April 2026.

Key aspects of this year's vaccination program include:

Eligibility: All Queensland residents are eligible for a free influenza vaccine. The National Immunisation Program (NIP) also funds specific vaccines for identified at-risk groups across Australia.
Vaccine Types: CSL Seqirus, an Australian manufacturer, is supplying cell-based and adjuvanted vaccines for both the private market and the NIP.
Needle-Free Options: The first needle-free flu vaccines for children are being introduced in Australia. These are available through state-based immunization programs in New South Wales, Queensland, South Australia, and Western Australia for children aged two to five years.
Access Points: Vaccines are readily accessible at General Practitioners (GPs), pharmacies, primary health centers in the Torres Strait, Cape York, and Northern Peninsula Area, and at specific hospital and health services.
Professional Role: GPs and pharmacists are playing a vital role in vaccination efforts. In 2025, pharmacists administered 2.6 million flu vaccines nationally, with a systematic review indicating that pharmacist-led vaccinations significantly increased uptake.

The 2026 flu vaccine rollout includes free options for all Queensland residents, NIP-funded vaccines for at-risk groups, needle-free options for young children, and wide accessibility through GPs and pharmacies.

ATAGI's 2026 Vaccination Advice

ATAGI has released its comprehensive 2026 influenza vaccination advice, strongly emphasizing annual vaccination due to the evolving nature of flu strains.

Importance of Advice: Recommendations from health professionals are identified as a primary factor influencing an individual's decision to vaccinate. Australia’s Chief Medical Officer, Professor Michael Kidd, has highlighted the crucial role of GPs in this regard.
Older Adults (65+ years): The NIP recommends both the NIP-funded adjuvanted vaccine (Fluad) and the private market high-dose influenza vaccine (Fluzone High-Dose) over standard influenza vaccines.
Individuals with Medical Conditions (5-64 years): Flucelvax is NIP-funded for individuals in this age group who have medical conditions that increase their risk of influenza complications. There is no preferential recommendation between Flucelvax and standard dose egg-based influenza vaccines for this group.
Co-administration: Influenza vaccines can be safely administered concurrently with other vaccines.
Continued Vaccination: Vaccination is advised to continue as long as influenza viruses are circulating and valid vaccines are available, even for those vaccinated in late 2025 or early 2026.
Tailored Advice: Specific guidelines are provided for various patient groups, including travelling patients, young children, pregnant women, Aboriginal and Torres Strait Islander People, older adults, and medically at-risk patients.

Prevention and Care: Staying Healthy

To prevent the spread of respiratory illnesses, good hygiene practices are recommended year-round:

Regular hand washing and sanitizing.
Covering coughs and sneezes.
Disposing of tissues immediately after use.
Maintaining physical distance from others when experiencing symptoms.

Individuals experiencing influenza symptoms are advised to:

Avoid work or school.
Stay home, rest, and consume plenty of fluids until symptoms resolve, typically within five to seven days.
Seek medical attention promptly if symptoms worsen, such as fast or difficult breathing, chest pains, increased sleepiness, or a general decline. Early care is important, particularly for those with chronic conditions, as antiviral treatments are most effective when started within the first few days of symptom onset.

Who's at Risk and What to Look For

Influenza and COVID-19 can lead to severe illness, especially in high-risk groups, including:

Young children.
Older adults.
Pregnant individuals.
Those with pre-existing chronic conditions.

RSV poses a significant risk to infants and young children, who are highly susceptible to contracting the disease and developing severe illness.

Common symptoms across these infections may include:

Runny nose
Cough
Fever
Sore throat
Headache

In infants and babies, RSV symptoms can also manifest as irritability, tiredness, refusal to feed, weight loss, or labored/fast breathing.